Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance.
Louie
Arnold
A
Ordway Research Institute, Albany, NY 12208, USA.
Bied
Adam
A
Fregeau
Christine
C
Van Scoy
Brian
B
Brown
David
D
Liu
Weiguo
W
Bush
Karen
K
Queenan
Anne-Marie
AM
Morrow
Brian
B
Khashab
Mohammed
M
Kahn
James B
JB
Nicholson
Susan
S
Kulawy
Robert
R
Drusano
G L
GL
D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001426:Bacterial Proteins / Q000235:genetics; D015780:Carbapenems / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000077726:Doripenem; D024881:Drug Resistance, Bacterial / Q000235:genetics; D005798:Genes, Bacterial; D006801:Humans; D015378:Imipenem / Q000008:administration & dosage / Q000493:pharmacokinetics; D066298:In Vitro Techniques; D008826:Microbial Sensitivity Tests; D009154:Mutation; D018272:Porins / Q000235:genetics; D016016:Proportional Hazards Models; D011552:Pseudomonas Infections / Q000188:drug therapy; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics / Q000302:isolation & purification; D013997:Time Factors; D001618:beta-Lactamases / Q000235:genetics
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D015780:Carbapenems; D018272:Porins; C077157:OprD protein, Pseudomonas aeruginosa; D015378:Imipenem; D000077726:Doripenem; C048795:AmpC beta-lactamases; D001618:beta-Lactamases